Leveraging Bispecific RNAi Approaches to Reduce Global Cardiovascular Risk

• Defining cardiovascular risk among a population with Atherosclerotic Cardiovascular Disease
• Using bispecific strategies to target appropriate cardiovascular receptors and markers
• Developing new RNAi medicines to reduce global cardiovascular risk

Speakers:

David Solomon

Chief Executive Officer

Thalia Therapeutics